Treace Medical Concepts, Inc. (NASDAQ:TMCI) Position Raised by Nuveen Asset Management LLC

Nuveen Asset Management LLC increased its stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) by 11.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 472,840 shares of the company's stock after purchasing an additional 48,525 shares during the quarter. Nuveen Asset Management LLC owned 0.76% of Treace Medical Concepts worth $3,518,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Treace Medical Concepts by 25.9% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 274,200 shares of the company's stock worth $2,040,000 after buying an additional 56,445 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Treace Medical Concepts by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,001 shares of the company's stock worth $208,000 after buying an additional 1,216 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in Treace Medical Concepts during the 4th quarter worth about $100,000. Bayesian Capital Management LP purchased a new stake in Treace Medical Concepts during the 4th quarter worth about $77,000. Finally, Bank of America Corp DE lifted its holdings in Treace Medical Concepts by 71.1% during the 4th quarter. Bank of America Corp DE now owns 144,068 shares of the company's stock worth $1,072,000 after buying an additional 59,848 shares during the last quarter. 84.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

TMCI has been the subject of a number of recent analyst reports. UBS Group decreased their price target on Treace Medical Concepts from $10.00 to $8.60 and set a "neutral" rating for the company in a report on Friday, May 9th. Truist Financial decreased their price target on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating for the company in a report on Friday, April 11th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $10.16.

Insider Buying and Selling at Treace Medical Concepts

In other Treace Medical Concepts news, insider Sean F. Scanlan sold 50,000 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $7.97, for a total value of $398,500.00. Following the transaction, the insider now directly owns 364,081 shares of the company's stock, valued at $2,901,725.57. This trade represents a 12.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.72% of the stock is owned by insiders.

Treace Medical Concepts Stock Performance

Shares of Treace Medical Concepts stock remained flat at $5.77 on Thursday. The stock had a trading volume of 266,430 shares, compared to its average volume of 579,520. The business has a 50-day moving average price of $6.76 and a 200 day moving average price of $7.93. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The firm has a market cap of $362.88 million, a PE ratio of -5.83 and a beta of 0.68. Treace Medical Concepts, Inc. has a fifty-two week low of $4.54 and a fifty-two week high of $10.79.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. The firm had revenue of $52.57 million during the quarter, compared to the consensus estimate of $52.07 million. Treace Medical Concepts had a negative return on equity of 51.12% and a negative net margin of 30.33%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.30) EPS. Analysts predict that Treace Medical Concepts, Inc. will post -0.92 EPS for the current fiscal year.

Treace Medical Concepts Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.